Never Mind Ginkgo Bioworks' Drama -- This Synthetic Biology Stock Is Still a Buy
The honeymoon for newly minted Ginkgo Bioworks (NYSE: DNA) shares recently came to an abrupt end, and it didn't take long. The synthetic-biology start-up just made its stock market debut in mid-September.
Propelled by Cathie Wood's endorsement, Ginkgo's stock market valuation reached $15 billion before the bottom fell out. A short-seller who stands to gain a great deal if the stock implodes knocked the stock off its perch recently, with a report that highlighted the company's reliance on related-party transactions.
Amyris (NASDAQ: AMRS) is a well-established synthetic-biology company that doesn't get half as much attention as Ginkgo Bioworks. It probably won't provide much drama, but it could push your portfolio into the clouds over the long run. Here's why it should be at the top of your list of growth stocks to buy.
Source Fool.com
